Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin or liraglutide added to standard therapy for psoriasis with metabolic syndrome
ChiCTR1900023294Phase 4Not yet recruiting
- Sponsor
- Department of Dermatology, Chinese PLA General Hospital
- Start
- Jun 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metformin and liraglutide in psoriasis and cardiometabolic risk (CMR) (3 arms), sponsored by Department of Dermatology, Chinese PLA General Hospital. Primary endpoint: Percentage achieving PASI75 at Week 12. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
metforminliraglutide
03
Conditions
psoriasiscardiometabolic risk (CMR)
Beyond the preview
Go deeper on ChiCTR1900023294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023294.